Updated Analysis From the Phase III MEDALIST Trial of Luspatercept to Treat Anemia in Lower-Risk RBC Transfusion-Dependent MDS With Ring Sideroblasts

December 7-10, 2019; Orlando, Florida
Longer-term analysis of the MEDALIST study showed that more luspatercept-treated patients attained transfusion independence for ≥ 8 weeks any time during therapy compared with placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: December 15, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Download these expert-selected slides on later-stage relapsed/refractory myeloma to help manage your patients, from Clinical Care Options (CCO).

Paul G. Richardson, MD Released: September 22, 2022

See key clinical insights fast, with this short slideset from CCO on relapsed/refractory myeloma, from Clinical Care Options (CCO).

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings